Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pitavastatin + aspirin
- Development stage
- Preclinical
- Lead developer
- Kowa
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of pitavastatin and aspirin used for cardiovascular disease management. Pitavastatin is a potent HMG-CoA reductase inhibitor that lowers LDL cholesterol, total cholesterol, and triglycerides while increasing HDL cholesterol. Aspirin is an antiplatelet agent that inhibits platelet aggregation to prevent blood clots. The combination provides dual protection against cardiovascular events through complementary mechanisms.
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on pitavastatin + aspirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pitavastatin + aspirin.